| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Profit before tax | -24.6 | -11.3 |
| Net income | -24.6 | -11.3 |
| EPS (diluted, $ a share) | $-1.70 | $-1.03 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: PVLA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Palvella Therapeutics, Inc.: key numbers
- Share price
- $144.60Close, Nov 16
- Market cap
- $2.11B
- Shares outstanding
- 14.62MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Palvella Therapeutics, Inc.
All →Palvella Therapeutics CSO Jeffrey S. Martini Sells $2.08M of Stock
Jeffrey S. Martini, CSO, sold 12,500 shares of Palvella Therapeutics, Inc. at $163.34 to $172.12 a share (average $166.65) in 13 transactions, worth $2.08M in total between Nov 10, 2026 and Nov 11, 2026. Shares held after the trade: 0 (-100.0%).
- Value
- $2.08M
- Shares
- 12,500
- Average price
- $166.65
- Role
- CSO
- Holding change
- -100.0%
- Trade date
- Nov 10, 2026 to Nov 11, 2026
Palvella Therapeutics Financial Results
Palvella Therapeutics reported third quarter 2026 financial results and provided a corporate update, highlighting the FDA's acceptance and Priority Review of its NDA for QTORIN™ rapamycin in microcystic lymphatic malformations. The company ended the quarter with $236.7 million in cash and is preparing for a potential U.S. commercial launch in the first half of 2027 following a February 28, 2027 PDUFA date.
- Term
- Q3 2026
“With the FDA’s acceptance of our NDA for QTORIN™ rapamycin in microcystic lymphatic malformations and granting of Priority Review, we believe we are closer than ever to bringing our first therapy to patients.”
Wes Kaupinen, Founder and Chief Executive Officer
“Our focus is clear: successfully obtain FDA approval and bring our first therapy to patients, advance multiple additional QTORIN™ programs to approval, and build the leading company addressing serious, rare skin diseases and vascular anomalies.”
Wes Kaupinen, Founder and Chief Executive Officer
Palvella Therapeutics Business Update
Palvella Therapeutics announced that the FDA has accepted its New Drug Application (NDA) for QTORIN™ 3.9% rapamycin anhydrous gel and granted it Priority Review. The application seeks approval for the treatment of microcystic lymphatic malformations, with a PDUFA target action date set for February 28, 2027.
Palvella Therapeutics COO Kathleen Goin Sells $537K of Stock
Kathleen Goin, COO, sold 4,313 shares of Palvella Therapeutics, Inc. at $123.62 to $126.19 a share (average $124.58) in 3 transactions, worth $537K in total on Oct 21, 2026. Shares held after the trade: 0 (-100.0%).
- Value
- $537K
- Shares
- 4,313
- Average price
- $124.58
- Role
- COO
- Holding change
- -100.0%
- Trade date
- Oct 21, 2026
Palvella Therapeutics Insider George M. Jenkins Sells $3.58M of Stock
George M. Jenkins sold 27,500 shares of Palvella Therapeutics, Inc. at $121.14 to $136.44 a share (average $130.16) in 17 transactions, worth $3.58M in total between Oct 12, 2026 and Oct 14, 2026. Shares held after the trade: 132,616 (-0.4%).
- Value
- $3.58M
- Shares
- 27,500
- Average price
- $130.16
- Holding change
- -0.4%
- Trade date
- Oct 12, 2026 to Oct 14, 2026
Palvella Therapeutics COO Kathleen Goin Sells $655K of Stock
Kathleen Goin, COO, sold 4,302 shares of Palvella Therapeutics, Inc. at $151.16 to $153.24 a share (average $152.24) in 3 transactions, worth $655K in total on Sep 16, 2026. Shares held after the trade: 0 (-100.0%).
- Value
- $655K
- Shares
- 4,302
- Average price
- $152.24
- Role
- COO
- Holding change
- -100.0%
- Trade date
- Sep 16, 2026